The place for short-acting opioids: special emphasis on remifentanil by Wilhelm, Wolfram & Kreuer, Sascha
Page 1 of 9
(page number not for citation purposes)
Available online http://ccforum.com/content/12/S3/S5
Abstract
Pain is among the worst possible experiences for the critically ill.
Therefore, nearly all intensive care patients receive some kind of
pain relief, and opioids are most frequently administered. Morphine
has a number of important adverse effects, including histamine
release, pruritus, constipation, and, in particular, accumulation of
morphine-6-glucuronide in patients with renal impairment. Hence, it
is not an ideal analgesic for use in critically ill patients. Although the
synthetic opioids fentanyl, alfentanil, and sufentanil have better
profiles, they undergo hepatic metabolism and their continuous
infusion also leads to accumulation and prolonged drug effects.
Various attempts have been made to limit these adverse effects,
including daily interruption of infusion of sedatives and analgesics,
intermittent bolus injections rather than continuous infusions, and
selection of a ventilatory support pattern that allows more spon-
taneous ventilation. However, these techniques at best only limit
the effects of drug accumulation, but they do not solve the
problem. Another type of approach is to use remifentanil in critically
ill patients. Remifentanil is metabolized by unspecific blood and
tissue esterases and undergoes rapid metabolism, independent of
the duration of infusion or any organ insufficiency. There are data
indicating that remifentanil can be used for analgesia and sedation
in all kinds of adult intensive care unit patients, and that its use will
result in rapid and predictable offset of effect. This may permit both
a significant reduction in weaning and extubation times, and clear
differentiation between over-sedation and brain dysfunction. This
article provides an overview of the use of short-acting opioids in
the intensive care unit, with special emphasis on remifentanil. It
summarizes the currently available study data regarding remifen-
tanil and provides recommendations for clinical use of this agent.
Introduction
Intensive care unit (ICU) patients suffer pain, which is among
the major stressors in the ICU [1], for various reasons. In
addition to surgery and trauma, pain can result from numer-
ous diagnostic and therapeutic procedures, including airway
management and ventilatory care, insertion of drains and
catheters, routine care such as mobilization, among many
others. Consequently, nearly all ICU patients need some kind
of pain medication, and opioids are most frequently adminis-
tered in this setting. Some years ago, a European investi-
gation into analgesia and sedation in the ICU [2] revealed
that the drugs most commonly used for analgesia were
morphine (33%), fentanyl (33%), and sufentanil (24%), and
also demonstrated substantial differences in analgesic
practice throughout Europe.
Morphine
Opioids are the mainstay of analgesia in the ICU. However,
these drugs have a number of adverse effects, and this is
especially true for morphine. Although all opioids may lead to
respiratory depression, it is important to bear in mind that the
morphine-6-glucuronide metabolite is more potent than
morphine itself, and that accumulation can occur, especially
in patients with renal impairment [3]. Typical adverse effects
of morphine include histamine release, pruritus, and, in
particular, constipation. Regarding the various national guide-
lines on the use of sedatives and analgesics in critically ill
adults, morphine use is included in the recommendations of
the American College of Critical Care Medicine (ACCM) and
of the Society of Critical Care Medicine (SCCM) [4]. In
contrast, the German Society of Anaesthesiology and Intensive
Care Medicine opted not to recommend the use of morphine
when opioids are needed for longer than 24 hours [5].
Fentanyl, alfentanil and sufentanil
These agents are synthetic opioids of the 4-anilidopiperidine
group and they are commonly used in the operating room.
These opioids also undergo hepatic metabolism, and their
continuous infusion can lead to accumulation as well as
prolonged drug effects. This is especially so in critically ill
patients, in whom drug clearance may be substantially
reduced because of illness, organ dysfunction, or concomitant
therapy. Therefore, use of fentanyl, alfentanil, and sufentanil
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as well as morphine in ICU patients is always accompanied
by concerns regarding drug accumulation, which potentially
can lead to prolonged respiratory depression and delayed
and unpredictable recovery. Fentanyl is available worldwide,
but alfentanil is not commonly used in North America [4], and
neither alfentanil nor sufentanil are licensed for use in ICU
patients in many countries.
When these opioids are compared, alfentanil is the drug with
the most rapid onset of action and the shortest duration of
effect. However, alfentanil is a substrate for different cyto-
chrome P4503A enzymes, and its metabolism and offset of
effect can underly interindividual variability due to poly-
morphic enzyme expression and can markedly be inhibited by
different drugs, including antibiotics and antifungal
medication [6]. Thus, although single bolus injections of
alfentanil are short acting, the effects of an infusion of
alfentanil in ICU patients are much less predictable, and so
this drug is not the ideal short-acting opioid for use in the
ICU.
Defining the place for a short-acting opioid
Since intensivists identified the potentially devastating impact
of accumulation of analgesic and sedative drugs on patient
outcomes, various attempts have been made to limit such
accumulation. Means include daily interruption of infusion of
sedatives and analgesics [7], intermittent bolus injections
rather than continuous infusions [8], and selecting ventilatory
support that permits more spontaneous than controlled venti-
lation [9], among many others. These techniques are discussed
in detail in the other reviews included in this supplement.
However, these techniques at best only limit the effects of
drug accumulation, but they do not solve the problem itself.
Therefore, a totally different approach is needed, one that
involves a drug that undergoes rapid and complete metabo-
lism, independent of the duration of infusion or any organ
insufficiency.
Remifentanil: pharmacology
Remifentanil is a potent selective μ-opioid receptor agonist
and was first approved for use as an analgesic agent during
induction and maintenance of general anesthesia in 1996. In
2002 remifentanil received approval from the European
Medicines Agency for provision of analgesia for a duration of
up to 3 days in mechanically ventilated ICU patients, aged
18 years or older.
Like fentanyl, alfentanil, and sufentanil, remifentanil is a 4-
anilidopiperidine μ-opioid analgesic. However, in contrast to
fentanyl and its congeners, remifentanil is completely
metabolized by unspecific esterases. In principle, esterases
are enzymes that break down esters into their alcohol and
acid components. The term ‘unspecific’ means that one
enzyme not only catalyzes a specific reaction but is also able
to break down other ester linkages, for example, that of
remifentanil. Because unspecific esterases are involved in
multiple steps in the metabolism of the living human cell, no
ICU disease or organ failure has yet been identified that can
cause reduced breakdown of remifentanil.
The major breakdown product of remifentanil is remifentanil
acid (RA), which is a relatively inactive carboxylic acid
metabolite with only 1/300 to 1/4,600 of the activity of
remifentanil [10,11]. In a rat model, the low in vivo potency of
RA was explained by a low affinity to the μ-opioid receptor in
combination with a poor brain penetration [12]. At least 88%
of the RA dose is eliminated in the urine in healthy, renally
nonimpaired adults, with a mean terminal elimination half-life
ranging from 88 to 137 minutes after bolus doses of
remifentanil of 2 to 30 μg/kg [13] (note that these bolus
doses by far exceed licensed use). The clearance of RA is
reduced in patients with impaired renal function, and the half-
life of RA increases to 14 to 32 hours in these patients
[14,15].
Because of its unique pharmacokinetic profile, remifentanil is
characterized by a rapid and uniform clearance and a highly
predictable onset and offset of effect [11]. Remifentanil has a
terminal half-life of approximately 10 to 20 minutes [16], and
its context-sensitive half-time is 3 to 4 minutes, regardless of
the duration of infusion [10]. In contrast, continuous infusions
of the other 4-anilidopiperidine opioids result in accumulation
and considerable prolongation of effect with increased
duration of infusion [10], making these opioids intermediate-
Figure 1
Context-sensitive half-times of remifentanil and the other 4-anilido-
piperidine opioids. Remifentanil has a context-sensitive half-time of 3 to
4 minutes, regardless of the duration of infusion, whereas continuous
infusion of the other opioids results in accumulation and considerable
prolongation of effect, making these opioids intermediate-acting or
long-acting agents, depending on the duration of infusion. Figure
adapted with permission from Egan TD, Lemmens HJ, Fiset P,
Hermann DJ, Muir KT, Stanski DR, Shafer SL: The pharmacokinetics of
the new short-acting opioid remifentanil (GI87084B) in healthy adult
male volunteers. Anesthesiology 1993, 79:881-892.
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acting or long-acting agents during prolonged infusion
(Figures 1 and 2).
First experiences with remifentanil in the
intensive care unit
Although remifentanil is not licensed for applications for
longer than 3 days, several of the reports reviewed here and
in other reviews included in this supplement have addressed
its use for longer periods.
The first experiences with the use of remifentanil in ICU
patients were reported shortly after remifentanil became
available for use in the operating room. In a case series of six
patients, Evans and Park [17] reported successful use of
remifentanil for analgesia and sedation during mechanical
ventilation for 3 to 33 days. The infusion rate ranged from
0.08 to 0.43 μg/kg per minute (modal values), and all patients
exhibited signs of recovery within 10 minutes of stopping the
remifentanil infusion. Similar findings were reported by
Soltész and coworkers [18], who examined the recovery of
ICU patients after trauma or major surgery. After 24 hours of
remifentanil infusion at a mean rate of 0.18 μg/kg per minute
and propofol infusion at 2.1 mg/kg per hour, all patients could
follow simple commands as early as 10 minutes after
stopping both infusions. In another study conducted in 46
ICU patients aged 62.8 ± 15.4 years [19], the mean duration
of remifentanil infusion was 9.8 hours and the mean dosage
was 0.14 ± 0.08 μg/kg per minute. Extubation was achieved
within 15 minutes of stopping the infusion in 31 patients
(67%) and within 45 minutes in 40 (87%); only in two of the
46 patients did recovery require longer than 120 minutes
(Figure 3).
Comparative studies of remifentanil and
other opioids
Within the ICU, remifentanil has been compared with various
other opioids in the management of critically ill patients
requiring mechanical ventilation.
Dahaba and colleagues [20] evaluated 40 mechanically
ventilated patients who received a blinded infusion of either
remifentanil 0.15 μg/kg per minute or morphine 0.75 μg/kg
per minute. Initially, the opioid infusion was titrated to reach an
optimal level of sedation (defined as Sedation Agitation Scale
score of 4), and a midazolam infusion was added only if further
sedation was deemed necessary. Although adverse events
were seldom and comparable in both groups, fewer infusion
rate adjustments were necessary in the remifentanil group,
and the percentage of time spent in optimal sedation was
greater for remifentanil than for morphine. Most important, the
mean duration of mechanical ventilation was significantly
shorter with remifentanil (14.1 ± 2.8 hours) than with morphine
(18.1 ± 3.4 hours), and the same was true for extubation times
(17 ± 6 minutes versus 73 ± 7 minutes) and intervals from
extubation until ICU discharge (20.7 ± 3.7 hours versus
41.7 ± 8.6 hours).
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Figure 2
Decline of effect site concentrations of different opioids after 24 hours
of infusion. The findings are expressed as percentage of the individual
maximum effect site concentration. This figure was calculated using
Stanpump simulation software (by Shafer S, University of Stanford,
CA, USA) for a female individual (age 80 years, height 170 cm, body
weight 80 kg) and the following infusion rates: remifentanil 0.15 μg/kg
per minute, sufentanil 1 μg/kg per hour, alfentanil 1.5 mg/hour, and
fentanyl 0.2 mg/hour.
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Figure 3
Extubation times after remifentanil infusion. Shown are extubation times
in 46 intensive care unit patients after sedation with a remifentanil
infusion (mean duration 9.8 hours, mean dosage 0.14 ± 0.08 μg/kg
per minute). Two-thirds of all patients could be extubated within
15 minutes and 87% within 45 minutes after cessation of remifentanil
infusion. Figure adapted with permission from: Wilhelm W, Dorscheid
E, Schlaich N, Niederprüm, Deller D: The use of remifentanil in critically
ill patients. Clinical findings and early experience. Anaesthesist 1999,
48:625-629. © Springer.
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after stopping remifentanil infusionIn another randomized, double-blinded study, Müllejans and
coworkers [21] examined 152 mechanically ventilated patients
who received either remifentanil (0.15 μg/kg per minute) or
fentanyl (1.5 μg/kg per hour). Opioid infusion rates could be
adjusted to reach an optimal level of sedation (defined as
Sedation Agitation Scale score of 4), and propofol 0.5 mg/kg
per hour was added when required. The mean percentages
of time spent in optimal sedation were similar in both groups
(88% to 89%), and only 35% of patients in the remifentanil
group and 40% of patients in the fentanyl group needed
additional propofol. Among those patients, however, the
required median total propofol dose was nearly twice as high
with fentanyl (683 mg) as with remifentanil (378 mg,
P = 0.065). Of note, recovery times were similar in both
groups (1.1 to 1.3 hours), probably because of the dosing
algorithm and the high frequency of monitoring and dosage
adjustments, which clearly prevented over-sedation in this
study.
In another study, Müllejans and colleagues [22] evaluated 80
patients who were mechanically ventilated for 12 to 72 hours
after having undergone cardiac surgery. Patients received
either remifentanil (0.1 to 1 μg/kg per minute [exceeding the
maximum licensed dose of 0.74 μg/kg per minute]) and
propofol (0.5 to 4.0 mg/kg per hour, added only in the case
of insufficient sedation at maximal remifentanil dose), or
fentanyl (1.0 to 7.0 μg/kg per hour) and midazolam (0.02 to
0.2 mg/kg per hour). Intervals from ICU admission to extub-
ation and to eligibility for discharge from the ICU were signi-
ficantly shorter after remifentanil/propofol (20.7 ± 5.2 hours
and 46.1 ± 22.0 hours) than after fentanyl/midazolam
(24.2 ± 7.0 hours and 62.4 ± 27.2 hours, P < 0.05), whereas
overall ICU costs were equal in the two groups, at about
€1,700/patient.
Baillard and colleagues [23] compared remifentanil (starting
dose 0.17 μg/kg per minute) and sufentanil (starting dose
0.125 μg/kg per hour), both combined with midazolam
(starting dose 0.1 mg/kg per hour), for long-term sedation in
41 critically ill adult patients requiring mechanical ventilation
in the ICU. Weaning times were significantly shorter after
remifentanil/midazolam (median 22 hours, interquartile
range 12 to 53 hours) than after sufentanil/midazolam
(median 96 hours, interquartile range 47 to 142 hours). It
must be emphasized that the midazolam doses used in this
investigation were relatively high, and this may in part
explain the long weaning times in both groups, especially
with remifentanil.
Remifentanil for neurosurgical and
neurotrauma patients
In patients with traumatic brain injury it has been demon-
strated that remifentanil can provide effective sedation during
transient painful procedures (for example, endotracheal
suctioning and physiotherapy), and no significant changes in
mean arterial blood pressure, intracranial pressure, or
cerebral blood flow velocity were observed [24]. In another
study of remifentanil in severely head injured patients [25],
reduction in coughing due to endotracheal suctioning was
dose dependent, but most patients needed vasopressors to
maintain cerebral perfusion pressure.
One of the most important issues in neuroanesthesia and
neurocritical care is neurologic assessment. Therefore,
cessation of analgesic and sedative infusions should be
accompanied by rapid and predictable awakening, thus
allowing clear differentiation between brain dysfunction and
over-sedation. Two studies have been conducted [26,27]
that compared remifentanil with fentanyl or morphine in
neurologic ICU patients.
In a randomized multicenter study, Karabinis and coworkers
[26] investigated mechanically ventilated patients who had
suffered acute brain injury or had undergone neurosurgery. A
total of 84 patients received remifentanil, with a median
weighted mean infusion rate of 0.26 μg/kg per minute,
combined with propofol (1.93 mg/kg per hour) during days 1
to 3 and then with midazolam (0.18 mg/kg per hour) on days
4 and 5. A second group of patients received a hypnotic-
based sedation with propofol on days 1 to 3, followed by
midazolam on days 4 and 5, combined with either fentanyl
(n = 37) or morphine (n = 40) according to routine clinical
practice. When fentanyl was used for analgesia, the median
weighted mean infusion rates were 3.6 μg/kg per hour for
fentanyl, 2.49 mg/kg per hour for propofol, and 0.11 mg/kg
per hour for midazolam. With morphine, the respective
infusion rates were 0.1 mg/kg per hour for morphine,
2.30 mg/kg per hour for propofol, and 0.13 mg/kg per hour
for midazolam. Patients were closely scored to achieve
optimal pain relief and sedation. Mean neurologic assessment
times were significantly shorter with remifentanil (0.41 hours)
than with fentanyl (0.71 hours) or with morphine (0.82 hours),
and patients were extubated significantly faster after
remifentanil (1.0 hour; median time from the start of the
extubation process until actual extubation) than after
morphine (1.93 hours), whereas no difference was observed
between remifentanil and fentanyl (0.68 hours). Furthermore,
neurological function assessment was judged excellent or
very good by 78% of those using remifentanil, but only by
25% of those using fentanyl and by 8% using morphine.
In a retrospective study conducted by Bauer and coworkers
[27], 60 patients were enrolled who were undergoing
supratentorial brain tumor surgery. General anesthesia as
well as ICU sedation consisted of either remifentanil/propofol
or fentanyl/midazolam. On the ICU, analgesic and sedative
infusions were dosed to reach a Ramsay Sedation Scale
score of 4 with remifentanil 0.1 to 0.2 μg/kg per minute and
propofol 0.5 to 3 mg/kg per hour, or with fentanyl 0.03 to
0.2 mg/hour and midazolam 2 to 12 mg/hour. Demographic
data and the duration of drug administration were
comparable for the remifentanil/propofol (528 ± 382 minutes)
Critical Care    Vol 12 Suppl 3 Wilhelm and Kreuer
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Mean extubation times were significantly shorter after remi-
fentanil/propofol (47 minutes) than after fentanyl/midazolam
(481 minutes), and the length of stay in the ICU was
significantly reduced (1.8 days versus 3.7 days). As a result
of prolonged unconsciousness and consequent inability to
conduct a neurologic assessment, a brain computed
tomography scan was performed in three patients who had
received fentanyl/midazolam to exclude neurosurgical
complications.
Impact of organ dysfunction
Multiple organ dysfunction or failure may complicate the
course of many critically ill patients and must therefore be
considered when analgesics and sedatives are valued for use
on the ICU. Since remifentanil is metabolised organ-indepen-
dently by unspecific esterases, organ dysfunctions do not
alter remifentanil pharmacokinetics, and this has especially
been proven for renal and hepatic impaiment [14,28,29].
However, although remifentanil is completely metabolized, its
main metabolite, RA, is renally excreted. Although RA has
only 1/300 to 1/4,600 of the activity of remifentanil [10,11], it
was nevertheless necessary to exclude the possibility of
prolonged μ-opioid effect. This was done in a comparative
study of 10 adult ICU patients with normal or mildly impaired
renal function and 30 patients with moderate or severe renal
impairment with a mean creatinine clearance of 14.7 ml/minute
[15,30]. All patients received remifentanil for up to 72 hours,
with the dosage starting with 0.1 to 0.15 μg/kg per minute.
Mathematical modeling revealed that remifentanil pharmaco-
kinetics were not significantly influenced by renal dysfunction,
but in patients with moderate or severe renal impairment RA
clearance was reduced to about 25% of normal values [15].
The metabolic ratio increased by 8-fold in the moderate/
severe group of renal dysfunction relative to the normal/mild
group, predicting average RA concentrations at steady state
more than 100-fold those of remifentanil in patients with
moderate/severe renal impairment [15]. Furthermore, based
on pharmacokinetic modelling, it was estimated that a
remifentanil infusion of 0.15 μg/kg per minute for up to
15 days would not result in RA concentrations that would
prolong opioid effects to a clinically significant degree [15]. In
the same type of patients, pharmacodynamic effects were
studied using scheduled down-titrations at 8, 24, 48, and
72 hours of infusion [30]. In this analysis the interval to offset
of opioid effect was more variable and statistically signifi-
cantly longer in the group of patients with moderate or severe
renal impairment. However, the time differences between
groups were of the order of minutes and were not clinically
important (about 17 minutes longer in the group of patients
with moderate or severe renal impairment after 72 hours of
remifentanil infusion; Figure 4). In summary, remifentanil can
be used to sedate ICU patients with severe renal dysfunction,
and dosage adjustments are not required.
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Figure 4
Times to offset of opioid effect after down-titration of remifentanil. Shown are times to offset of opioid effect after scheduled down-titrations (SDT)
of remifentanil at 8, 24, 48, and 72 hours of infusion in (a) 10 adult intensive care unit patients with normal or mildly impaired renal function and 
(b) 30 patients with moderate or severe renal impairment with a mean creatinine clearance of 14.7 ml/minute. Offset times were more variable and
statistically significantly longer in the renal impairment group (b). However, the time differences between the groups were only in the order of
minutes and without clinical importance (about 17 minutes longer [mean] in the renal impairment group after 72 hours of remifentanil infusion).
Adapted with permission from Breen and coworkers [30].
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Mean time difference of about 17 minutesWith regard to hepatic function, it has been demonstrated
that the pharmacokinetics of remifentanil and RA do not
significantly differ between patients with hepatic impairment
and healthy volunteers, so no dose adjustments are neces-
sary for hepatic impairment [28,29]. However, Dershwitz and
colleagues [28] have demonstrated that individuals with
severe hepatic impairment may be more sensitive to the
ventilatory depressant effects of remifentanil. Because of its
organ-independent metabolism, remifentanil appears to be
the ideal agent for sedation of patients with severe liver
disease, but its increased ventilatory depressant effect must
be taken into consideration, for example, when intubated ICU
patients are allowed to breathe spontaneously.
Analgesia-based versus hypnotic-based
sedation
Because of its pharmacologic properties, remifentanil allows
a complete re-design of ICU sedation, away from a
‘traditional’ hypnotic-based regimen to an analgesic-based
technique, with the objective being to achieve an awake and
pain-free ICU patient. This concept is called ‘analgesia-based
sedation’ [31,32].
Park and coworkers [32] compared 111 patients receiving
hypnotic-based sedation (mainly midazolam and propofol)
with 96 patients managed using an analgesia-based tech-
nique (mainly remifentanil) during two consecutive 12-week
periods. About one-third of the remifentanil patients (37%)
required no additional hypnotic, and in the remaining patients
the necessary amount of propofol was reduced. Moreover,
the number of patients with satisfactory levels of sedation
during synchronized intermittent mandatory ventilation was
significantly higher in the analgesia-based sedation group.
Breen and colleagues [31] investigated 105 ICU patients
requiring mechanical ventilation for up to 10 days. In the
analgesia-based group (n = 57) patients received remifentanil
starting with 0.1 to 0.15 μg/kg per minute, and midazolam
could be added if needed once the remifentanil dosage had
surpassed 0.2 μg/kg per minute; at remifentanil levels of
0.3 μg/kg per minute or greater, midazolam boluses were
used for sedation. In the conventional hypnotic-based group,
48 patients received midazolam, and fentanyl or morphine
were added as needed. The time from start of study drug
treatment to extubation was significantly shorter with remifen-
tanil than in the hypnotic-based group (94 hours versus
147.5 hours [data are 75th centiles]), and the same was true
for time from weaning to extubation (0.9 hours versus
27.5 hours [data are 75th centiles]). Of note, remifentanil was
infused for up to 10 days, and between days 3 and 10 there
were no signs of development of tolerance.
Possible concerns surrounding use of
remifentanil
Remifentanil has in general exhibited good tolerability in ICU
patients, and hypotension, bradycardia, and nausea have
been the adverse events most frequently reported in major
clinical trials in mechanically ventilated critically ill patients
[21,26]. In a study conducted in cardiac surgical patients
[22] the total numbers of adverse events were similar with
remifentanil/propofol and with midazolam/fentanyl. However,
although in the remifentanil/propofol group significantly more
drug-related events were observed (including shivering and
pain), respiratory insufficiency only occurred with midazolam/
fentanyl in three of the 39 patients and did not occur with
remifentanil [22]. Other possible adverse events that have
been reported with remifentanil, primarily in the anesthesia
literature, are thoracic and muscle rigidity and shivering [33].
Thoracic and muscle rigidity may occur when higher doses of
a rapid-onset opioid are injected (for example, a remifentanil
bolus dose of 1 μg/kg or more), and this may lead to severe
problems with mask ventilation or pressure-controlled
ventilation. Therefore, remifentanil bolus doses should be
limited to 0.5 μg/kg or omitted, and a muscle relaxant may be
used if ventilatory support is needed immediately. The
Summary of Product Characteristics (SmPC) for remifentanil
states that “bolus doses are not recommended in the
intensive care setting”.
The possible development of tolerance has been another
issue of concern with the use of remifentanil in ICU patients.
Tolerance phenomena can occur with all opioids, but even
with a prolonged remifentanil application (up to 10 days) the
weighted mean infusion rate of remifentanil rose only slightly
until day 3 and then was constant until day 10 [31].
With discontinuation of remifentanil the possible onset of
pain necessitates an individualized approach to pain manage-
ment in ICU patients, for instance, the application of a longer
acting opioid (for example, 5 to 10 mg morphine or 3 to
7.5 mg piritramide about 30 minutes before the remifentanil
infusion is turned off), possibly combined with a nonopioid
analgesic. (Piritramide is a synthetic opioid for postoperative
pain therapy with a mean duration of action of 4 to 6 hours
that is used in several European countries [for population
pharmacokinetics, see Bouillon and coworkers [34].) In
addition, use of a longer acting μ-opioid analgesic will reduce
the probability of shivering, which may occur after use of
remifentanil. However, the individual level of pain may differ
substantially between a patient with pneumonia-induced
respiratory insufficiency and a trauma victim, emphasizing the
need for individualized treatment.
Remifentanil in clinical practice
To administer remifentanil in mechanically ventilated intensive
care patients in accordance with its licence (also see the
SmPC), the following sequence may help to structure the
process:
1. Conduct a clinical evaluation of the patient.
2. Initiate a remifentanil infusion at an adequate dosage. The
recommended starting dose is between 0.1 and
Critical Care    Vol 12 Suppl 3 Wilhelm and Kreuer
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for a 70 kg patient.
3. Titrate remifentanil in increments of 0.025 μg/kg per
minute to achieve the desired level of analgesia. When
titrating remifentanil to the individual patient need, a
period of at least 5 minutes should be allowed between
dose adjustments.
4. If a dosage of 0.2 μg/kg per minute remifentanil is reached
and further sedation is necessary, add a hypnotic agent.
5. Adapt the required remifentanil and hypnotic dosage to
the individual patient’s needs at any given time.
6. Because of the rapid offset of action of remifentanil, no
residual opioid activity will be present within 5 to 10 minutes
after discontinuation, regardless of the duration of infusion.
Therefore, careful planning of the transition to longer
acting analgesia is necessary (for example, longer acting
opioids should be given at an appropriate dose before
discontinuation of remifentanil).
7. If the patient is ready for weaning, then titrate the
remifentanil infusion down in adequate steps (see SmPC
for details). This will circumvent the possibility that
patients might experience discomfort and become
agitated when remifentanil is abruptly discontinued.
8. Analgesia and sedation should be monitored closely
during the entire procedure. Therefore, the development
of standard operating procedures by each individual
clinical department is recommended.
In our department it is our practice in most patients to begin
with a combination of remifentanil and propofol 2% [33]. We
dilute 5 mg remifentanil in 50 ml saline 0.9%, resulting in a
concentration of 100 μg/ml. At arrival of the patient in the
ICU, both the remifentanil and the propofol syringe pumps are
started at 4 to 6 ml/hour (6 ml/hour of the remifentanil
infusion is a little less than 0.15 μg/kg per minute in the 70 kg
patient; 6 ml/hour propofol 2% is a little less than 2 mg/kg
per hour in the 70 kg patient). In old, small, or hemo-
dynamically unstable patients, it may be necessary to start the
remifentanil and propofol infusion pumps at 2 to 4 ml/hour.
If the patient is not sufficiently sedated then the propofol
infusion is increased by 2 ml/hour, and if the patient com-
plains or exhibits signs of pain then the remifentanil infusion is
increased by 2 ml/hour. If the combination of analgesia and
sedation is judged ‘too deep’, then both infusion rates are
reduced by 2 ml/hour.
Safety advice
The nursing staff must be informed that, because of the rapid
offset of action, remifentanil syringes must be changed
immediately. When the application of remifentanil is finished,
the three-way stopcock and infusion line must be flushed.
This is necessary to prevent an unintended remifentanil bolus
many hours later when the stopcock or infusion line are used
again (for instance, for administration of an antibiotic).
Furthermore, use of remifentanil in extubated patients is not
recommended. All mixtures of remifentanil with infusion fluids
should be used immediately.
For propofol it must be emphasized that the propofol syringe
must be filled aseptically and immediately before use.
Furthermore, the German propofol SmPC recommends that
one propofol syringe should not be used for more than
12 hours, and propofol should not be used for more than 7 days
in total.  In order to prevent a propofol infusion syndrome, we do
not use more than 4 mg/kg per hour of propofol in ICU patients.
Because in our departments we only care for adult patients, we
have limited the use of propofol 2% to 10 ml/hour (which equals
200 mg/hour). If a greater dosage is deemed necessary by the
nursing staff, then they must consult the ICU physician. If
propofol 4 mg/kg per hour is insufficient for sedation in the ICU
patient, then 5 mg bolus doses of midazolam may be added
every 4 to 8 hours as needed.
How to introduce remifentanil on the
intensive care unit
It is important to bear in mind that remifentanil is currently
licensed for provision of analgesia in mechanically ventilated
adult ICU patients for up to 72 hours only. Because of the
unique properties of remifentanil, it may be prudent to run the
first remifentanil protocols in patients who will probably be
ventilated for only a brief period of time (for example,
postoperatively). When the entire ICU staff is experienced
with the use of remifentanil, further groups of patients can be
selected based on the strengths and properties of remifen-
tanil. Examples of such groups include patients with renal or
liver impairment, neurologic or neurosurgical patients, patients
admitted to the ICU with an unclear diagnosis, and patients in
whom weaning and extubation are planned within the next
3 days.
Conclusion
Although nearly all mechanically ventilated ICU patients
require infusions or repeated bolus doses of opioids for pain
relief, their use may be associated with multiple problems, the
foremost being accumulation and prolonged drug effect. A
different approach is to use remifentanil, which is metabolized
by unspecific blood and tissue esterases and undergoes
rapid metabolism, independent of the duration of infusion or
any organ insufficiency. Remifentanil can be used for
analgesia and sedation in all kinds of adult ICU patients,
either alone or in combination with other sedatives. Further-
more, it has a rapid and predictable offset of effect,
potentially allowing either significant reductions in weaning
and extubation times or clear differentiation between over-
sedation and brain dysfunction.
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